Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.71 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122356 | 0.89 | SLC6A4 (0.65) | SLC6A4TNFSF11TNFMAPT | |
| SCHEMBL1228350 | 0.85 | SLC6A4 (0.66) | SLC6A4MAPT | |
| SCHEMBL428829 | 0.83 | SLC6A4 (1.00) | SLC6A4 | |
| SCHEMBL28785245 | 0.82 | SLC6A4 (0.70) | SLC6A4 | |
| SCHEMBL1703585 | 0.82 | SLC6A4 (0.67) | SLC6A4MAPT | |
| SCHEMBL1232327 | 0.82 | SLC6A4 (0.50) | SLC6A4MAPT | |
| SCHEMBL3233304 | 0.82 | SLC6A4 (0.67) | SLC6A4MAPT | |
| Maleic Acid SCHEMBL7864900 | 0.81 | SLC6A4 (0.66) | SLC6A4 | |
| Fumaric Acid SCHEMBL7864904 | 0.81 | SLC6A4 (0.66) | SLC6A4 | |
| Fumaric Acid SCHEMBL7864906 | 0.81 | SLC6A4 (0.66) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3027603-A2 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2016-06-08 | — | — | EP | disclosed |
| CN-105492434-A | Heterobicycloaryl RORC2 inhibitors and methods of use thereof | PFIZER | 2016-04-13 | — | — | CN | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| EP-2134689-A2 | INHIBITORS OF FOCAL ADHESION KINASE | The Scripps Research Institute (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| CN-101247853-A | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC (CA) | 2008-08-20 | — | — | CN | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282304-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | SLC6A4 4728/4885TNFSF11 1285/4885TNF 598/4885 |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | SLC6A4 4728/4885TNFSF11 1285/4885TNF 598/4885 |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | SLC6A4 215/4885TNFSF11 2679/4885TNF 1492/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | SLC6A4 4728/4885TNFSF11 1285/4885TNF 598/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | SLC6A4 215/4885TNFSF11 2679/4885TNF 1492/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | SLC6A4 4728/4885TNFSF11 1285/4885TNF 598/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | SLC6A4 4728/4885TNFSF11 1285/4885TNF 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.